Tenax Therapeutics, Inc. (TENX): Total Liabilities
$7.16M
As of 2025-12-31
$8.07M
As of 2026-06-30
+55.3%
3-year compound annual growth
+26.1%
5-year compound annual growth
-5.5%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.16M | +52.5% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $4.69M | +30.8% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $3.59M | +87.6% | 2025-03-25, Balance as of period end |
| 2022-12-31 | $1.91M | +9.4% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $1.75M | -22.1% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $2.24M | -13.5% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $2.59M | +65.6% | 2021-04-16, Balance as of period end |
| 2018-12-31 | $1.57M | +55.2% | 2020-03-30, Balance as of period end |
| 2017-12-31 | $1.01M | -83.7% | 2019-04-01, Balance as of period end |
| 2016-12-31 | $6.20M | -50.7% | 2018-04-02, Balance as of period end |
| 2015-12-31 | $12.56M | n/a | 2017-03-16, Balance as of period end |
| 2015-04-30 | $12.48M | +18.4% | 2015-07-14, Balance as of period end |
| 2014-04-30 | $10.54M | +112.6% | 2015-07-14, Balance as of period end |
| 2013-04-30 | $4.96M | +10.5% | 2014-07-29, Balance as of period end |
| 2012-04-30 | $4.49M | -32.5% | 2013-06-26, Balance as of period end |
| 2011-04-30 | $6.65M | n/a | 2012-07-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $7.16M | +52.5% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $71.53B | -6.1% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $10.78M | -5.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $121.39B | -2.8% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $117.67B | +8.3% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
| Provectus Biopharmaceuticals, Inc. (PVCT) | 2025-12-31 | $7.00M | +0.4% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $3.14M | -44.7% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $241.54M | -9.5% |
Compare TENX, BMY, TXMD, PFE side by side · Screen every company in Pharmaceutical Preparations ↗